Provectus announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.
Provectus announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.
Provectus today announced that it will be participating in a panel discussion at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact. The conference will be held April 28-30, 2016, in Vatican City, and hosted by the Vatican's Pontifical Council for Culture, The Stem For Life Foundation and the STOQ (Science, Theology and the Ontological Quest) Foundation.
Provectus announced today that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "T cell Mediated Immunity After Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model," at the American Association for Cancer Research (AACR) Annual Meeting 2016, held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Provectus today announced that an abstract titled Intralesional rose bengal for treatment of melanoma has been accepted for a poster presentation at the annual meeting of the American Society of Clinical Oncology being held in Chicago June 3-7, 2016.
Provectus today announced its financial results for the fourth quarter and year ended December 31, 2015.
Provectus today announced that it will host its 2015 year-end quarterly financial business update conference call on Wednesday, March 30, 2016, at 4:00 p.m. Eastern Daylight Time.
Provectus announced today that the abstract for an upcoming poster presentation of data on intralesional PV-10 and co-inhibitory blockade and mechanisms of T cell mediated immunity in a melanoma model is now publicly available.
Provectus today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma.
Provectus announced today that the Audit Committee of its Board of Directors (the "Committee") has conducted an internal investigation that was initiated by the Committee in connection with the February 2016 resignation of the Company's former chief executive officer, Dr. H. Craig Dees. The Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Committee in conducting the investigation. As part of the investigation, the Committee reviewed the Company's financial policies and procedures, including management expenses.
Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Wednesday, March 16, 2016, at 4:00 p.m. Eastern Daylight Time.
Provectus today announced that it is changing the date for its fourth quarter and year-end conference call to Wednesday March 16, 2016, from March 10, 2016. The call will take place at 4 pm EDT that day.
Provectus today announced that it has received a patent from the U.S. Patent and Trademark Office, U.S. Patent No. 9,273,022.
Provectus today announced that it will host a conference call at 4 PM Eastern Standard Time, on Tuesday, March 1, 2016. The purpose of the call will be to discuss recently announced changes in the Company's leadership stemming from the resignation of H. Craig Dees, PhD, as Chairman and CEO.
Provectus today announced that it is initiating a protocol titled, "A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products."
Provectus announced today several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD.
Provectus today announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research's ("AACR") Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.
Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Thursday, March 10, 2016, at 4:00 p.m. Eastern Standard Time.
Provectus today announced data discussing the immunologic effects of PV-10 on colon cancer cells were presented yesterday at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.
Provectus today announced that it will present at the 18th Annual BIO CEO & Investor Conference.
(c) 2002-2016 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.